Vyleesi® product results: 14% growth in prescriptions dispensed over prior quarter – 6 consecutive quarters of double digit growth.
Click here to learn more ›

December 2014

Palatin Announces Start of Bremelanotide Phase 3 Program For Female Sexual Dysfunction

Press Releases / By

Triggers euro 2.5 Million (~$3 Million) Milestone Payment from Gedeon Richter CRANBURY, N.J., Dec. 29, 2014 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical needs and commercial potential, today announced that it has started its bremelanotide pivotal registration program.  …

Palatin Announces Start of Bremelanotide Phase 3 Program For Female Sexual Dysfunction Read More »

Palatin Completes $20 Million Equity and $10 Million Debt Financings

Press Releases / By

CRANBURY, N.J. and FARMINGTON, Conn., Dec. 24, 2014 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced that it has closed on a private placement of 2,050,000 shares of its common stock and …

Palatin Completes $20 Million Equity and $10 Million Debt Financings Read More »

Scroll to Top